Windlas Biotech Limited, a prominent pharmaceutical CDMO in India, recently obtained Good Manufacturing Practices (GMP) certification for its new injectable manufacturing facility from Uttarakhand’s Food Safety & Drugs Administration Authority. This certification, granted after a successful inspection in December 2024, confirms that the facility complies with WHO TRS Guidelines.
The certification marks a significant milestone for Windlas Biotech Limited, as it signals the company’s commitment to upholding high-quality standards in its manufacturing processes. The newly certified facility is equipped with advanced automated systems and stringent quality control mechanisms, making it the company’s fifth GMP-compliant manufacturing plant.
Hitesh Windlass, the Managing Director of Windlas Biotech Limited, expressed his satisfaction with the certification, stating that it would allow the company to enhance its product offerings in the CDMO sector. With the growing demand for injectable pharmaceutical products both domestically and globally, the certification positions Windlas Biotech Limited to expand its market presence and meet the needs of a wider customer base.
Having established itself as one of the top five pharmaceutical formulations CDMO players in India, Windlas Biotech Limited brings over twenty years of experience in manufacturing solid and liquid pharmaceutical dosage forms. The company specializes in producing high potency and controlled substances, as well as marketing branded trade generics and institutional products across the country.
The GMP certification will enable Windlas Biotech Limited to further diversify its manufacturing capabilities, particularly in the production of sterile injectable formulations. The new facility features environmentally-friendly processes and state-of-the-art infrastructure, designed to facilitate the efficient production of sterile injectables across a broad spectrum of therapeutic areas.
In conclusion, Windlas Biotech Limited’s achievement of GMP certification for its injectable manufacturing facility underscores the company’s dedication to excellence and innovation in the pharmaceutical industry. With a strong focus on quality and compliance, Windlas Biotech Limited is poised to make significant strides in the CDMO space and continue providing high-quality healthcare solutions to its customers.
